The occurrence of orthotopic prostate tumors was 29/33 (88%) in the PC-3/VEGF-C group and 24/28 (86%) in the PC-3/mock group, when they were measured in the end of the experiment. The gene discussed is VEGFC; the disease is prostate neoplasm.